CYP19A1 and breast cancer: In the neoadjuvant setting postmenopausal patients with EGFR-positive, and ERα-positive breast cancer were randomized for gefitinib (EGFR tyrosine kinase inhibitor) alone or gefitinib plus anastrazole, an aromatase inhibitor.